How to reconstitute IGF-1 LR3: mixing and storage
An unapproved growth signal with no human trials found.
Also called: Long R3 IGF-I, Long Arg3 IGF-1, LR3-IGF-1, Long-[Arg3]IGF-I.
IGF-1 and analogues · Modified IGF-1 receptor agonist · Evidence: Animal studies only.
Comes as: Community-reported lyophilized powder vials.
Mixed with: Community posts use bacteriostatic water or discuss dilute acetic acid. No human-use diluent is established..
Common vial sizes: 1 mg. Common water amounts: 2, 3 mL.
- One guide describes 1 mg with 2 mL or 3 mL bacteriostatic water. These are community examples.
- Comments disagree about acid versus water and degradation. No validated sterility or stability data settle this.
- Mixing does not remove endotoxin, impurities or an incorrect peptide.
Before mixing: No validated human-use storage specification located.
After mixing: Posts advise refrigeration; a reliable post-mixing shelf life is unknown.
Related to IGF-1 LR3
- Mecasermin: Prescription IGF-1 approved for rare childhood growth failure; low blood sugar is a major risk.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Somatropin: Prescription human growth hormone, with no proven anti-aging benefit.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- INCRELEX (mecasermin) injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Low blood sugar (hypoglycaemia), NHS · 2023
- Tailor Made Compounding LLC - 594743 - 04/01/2020, FDA · FDA · 2020
- Increlex, European Medicines Agency
- Increlex, INN-mecasermin, European Medicines Agency
- Know When to Go to the ER, American College of Emergency Physicians · American College of Emergency Physicians
- Mecasermin (Increlex▼): risk of benign and malignant neoplasia, MHRA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.